Cornea

A national poll suggests most parents overlook simple steps to protect children’s eyes; 1 in 7 parents say their child has not had a vision test in 2 years.

The company and its U.S. joint venture partner and licensee, HLB Therapeutics, signed a letter of intent this week with a global ophthalmology contract research organization to conduct a pair of phase 3 clinical trials simultaneously beginning in the fall in the U.S. and Europe for patients with neurotrophic keratitis.

University of Chicago Medical Center investigators reviewed 2 years of data on assaults with paintball guns found more patients than expected suffered vision-threatening emergencies after being struck in the eye, with several experiencing a rupture of the eyeball or even permanent blindness.

Cynthia Matossian, MD, FACS, ABES, explains why eye care professionals should oversee the selection and use of artificial tears for patients with dry eye.

According to the company, the study found a positive safety and tolerability profile for aCT1 for treatment of corneal injury.

The University of Oklahoma Health Sciences Center has received an unrestricted grant from Research to Prevent Blindness for $575,000 over 5 years to support eye research conducted by the Department of Ophthalmology.

Kala Pharmaceuticals Inc. announced that it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was first announced in May.

According to William B. Trattler, MD, progression of the disease before cross-linking often can be identified over a period of months.

Kiora Pharmaceuticals announced it has enrolled the first patient as a part of a Phase 2 study evaluating KIO-201 topical eye drops in patients with PCED, a rare ocular surface condition characterized by non-healing wounds on the eye surface.

According to Mark Lobanoff, DO, earlier treatment also can mean the best possible results for patients.

Kiora Pharmaceuticals announced it has enrolled the first patient as a part of a Phase 2 study evaluating KIO-201 topical eye drops in patients with PCED, a rare ocular surface condition characterized by non-healing wounds on the eye surface.

RegeneRx Biopharmaceuticals Inc. said its U.S. joint venture partner and licensee, HLB Therapeutics, will expand its ophthalmic clinical development program with RGN-259 in two indications, neurotrophic keratopathy and dry eye disease.

A study by Orbis International found that children with myopia experienced significantly higher levels of depression and anxiety than their peers without vision impairment.

As dexamethasone adds indications, a study confirms efficacy of punctal occlusion for allergic conjunctivitis.

The treatments typically include application of heat, lid hygiene, and massage of eyelid.

Takeaway: there doesn't seem to be a specific dry eye phenotype that does better or worse.

Biologic treatments can be utilised to help the eye heal itself in inflammatory conditions such as dry eye disorder.

Eye rubbing is an essential factor in the development of keratoconus. “No rub, no cone” is the rule: a genetic predisposition for the disease will come to nothing without excessive eye rubbing.

According to researchers from the Doherty Institute, the cornea produces a delicate and limited immune response to fight infections without damaging a patient's vision.

The study evaluates three separate cases, each of which experienced irreversible changes in their corneal structure caused by challenges in getting timely treatment due to various reasons, including insurance, lost to follow up, and the COVID-19 pandemic.

In a paper, investigators identified strategies used by patients to reduce the cost of therapy and its impact on adherence to treatment. Patients may be reluctant to disclose challenges regarding adherence to dry eye disease therapy, as well as fears of worsening quality of life.

Physicians offer pearls for improving visualisation in eyes using retroillumination techniques.

The Phase 3 registrational study is examining AR-15512, a differentiated, novel product candidate for the treatment of the signs and symptoms of Dry Eye Disease

According to the companies, Kala will receive $60 million in upfront payment, and could be eligible to receive additional sales-based milestone payments.

The study's primary endpoints were to look at increasing Schirmer's scores, as well as eye discomfort score.